Metraipolis › archive › dc_a413174de4b9
Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma — Europe PMC PMID:40989700
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/40989700
- DOI
- 10.3389/fonc.2025.1608291
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-10T01:58:14.141Z
- SHA-256 of the archived text
61eb885a8734c2bb6fb9a6046995bfff96e9fcb2ba167da6902417e3e5681f69- Stable URL of this page
https://metraipolis.com/documento/dc_a413174de4b9
How to cite
Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma — Europe PMC PMID:40989700 — Europe PMC (en), https://europepmc.org/article/MED/40989700 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_a413174de4b9 (Metraipolis archive dc_a413174de4b9, sha256 61eb885a8734c2bb6fb9a6046995bfff96e9fcb2ba167da6902417e3e5681f69)
BibTeX
@misc{dca413174de4b9,
title = {Case report series: Pembrolizumab and enfortumab vedotin in plasmacytoid urothelial carcinoma — Europe PMC PMID:40989700},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/40989700},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_a413174de4b9; sha256 61eb885a8734c2bb6fb9a6046995bfff96e9fcb2ba167da6902417e3e5681f69},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40989700. Agents can read the archived copy with the MCP tool read_document.